Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma

  • Original Paper
  • Published:
Cellular Oncology Aims and scope Submit manuscript

Abstract

Purpose

Several prognostic models have been developed to assess the efficacy and safety of sorafenib for metastatic renal cell carcinoma (mRCC), but few studies have validated its use in Chinese patients. The objective of this single center, single arm retrospective study was to examine the efficacy and safety of sorafenib and its related prognostic clinico-pathologic factors in Chinese mRCC patients.

Methods

One hundred thirty four mRCC patients were enrolled. All patients received 400 mg of sorafenib orally twice daily. The dose was subsequently adjusted in the event of treatment-induced toxicity. Tumor response, progression-free survival (PFS), overall survival (OS) and adverse events (AEs) were determined.

Results

The median PFS and OS were 10 months (1–36 months) and 22 months (2–37 months), respectively. Complete, partial, and stable disease were observed in two (1.49 %), 24 (17.91 %), and 99 (73.88 %) patients, respectively. Hand/foot skin reactions, diarrhea and fatigue were the most commonly observed AEs following sorafenib treatment. Among the AEs, only 13 grades 3 and 4 were observed. Multivariate analysis revealed that independent predictive factors for PFS included Eastern Cooperative Oncology Group (ECOG) status, Memorial Sloan-Kettering Cancer Center (MSKCC) risk status, and bone metastasis (all p < 0.05). Factors associated with OS included MSKCC risk values, bone metastasis and sorafenib-induced hypertension (all p < 0.05).

Conclusion

The introduction of sorafenib therapy for mRCC in Chinese patients may lead to a favorable disease control with acceptable tolerability. In addition, the parameters predicting favorable outcomes, including ECOG status, MSKCC risk status and bone metastasis, may have prognostic value in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. B. Ljungberg, N.C. Cowan, D.C. Hanbury, M. Hora, M.A. Kuczyk, A.S. Merseburger, J.J. Patard, P.F. Mulders, I.C. Sinescu, European Association of Urology Guideline Group, EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58, 398–406 (2010)

    Article  PubMed  Google Scholar 

  2. C.L. Martel, P.N. Lara, Renal cell carcinoma: current status and future directions. Crit. Rev. Oncol. Hematol. 45, 177–190 (2003)

    Article  PubMed  Google Scholar 

  3. J. Bellmunt, M. Fishman, T. Eisen, D. Quinn, Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert. Rev. Anticancer. Ther. 10, 825–835 (2010)

    Article  CAS  PubMed  Google Scholar 

  4. H.T. Cohen, F.J. McGovern, Renal-cell carcinoma. N. Engl. J. Med. 353, 2477–2490 (2005)

    Article  CAS  PubMed  Google Scholar 

  5. F. Rasmussen, Metastatic renal cell cancer. Cancer Imaging 13, 374–380 (2013)

    Article  PubMed Central  PubMed  Google Scholar 

  6. B.I. Rini, Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. Nat. Clin. Pract. Oncol. 3, 602–603 (2006)

    Article  CAS  PubMed  Google Scholar 

  7. R.J. Motzer, N.H. Bander, D.M. Nanus, Renal-cell carcinoma. N. Engl. J. Med. 335, 865–875 (1996)

    Article  CAS  PubMed  Google Scholar 

  8. K.T. Flaherty, Sorafenib in renal cell carcinoma. Clin. Cancer Res. 13, 747s–752s (2007)

    Article  CAS  PubMed  Google Scholar 

  9. M.J. Ratain, T. Eisen, W.M. Stadler, K.T. Flaherty, S.B. Kaye, G.L. Rosner, M. Gore, A.A. Desai, A. Patnaik, H.Q. Xiong, E. Rowinsky, J.L. Abbruzzese, C. Xia, R. Simantov, B. Schwartz, P.J. O’Dwyer, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505–2512 (2006)

    Article  CAS  PubMed  Google Scholar 

  10. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Negrier, C. Chevreau, E. Solska, A.A. Desai, F. Rolland, T. Demkow, T.E. Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov, R.M. Bukowski, TARGET Study Group, Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007)

    Article  CAS  PubMed  Google Scholar 

  11. B. Escudier, C. Szczylik, T.E. Hutson, T. Demkow, M. Staehler, F. Rolland, S. Negrier, N. Laferriere, U.J. Scheuring, D. Cella, S. Shah, R.M. Bukowski, Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1280–1289 (2009)

    Article  CAS  PubMed  Google Scholar 

  12. C. Guevremont, C. Jeldres, P. Perrotte, P.I. Karakiewicz, Sorafenib in the management of metastatic renal cell carcinoma. Curr. Oncol. 16, S27–32 (2009)

    Article  PubMed Central  PubMed  Google Scholar 

  13. G. Procopio, E. Verzoni, I. Testa, N. Nicolai, R. Salvioni, F. Debraud, Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther. Adv. Urol. 4, 303–313 (2012)

    Article  PubMed Central  PubMed  Google Scholar 

  14. H. Zhang, B. Dong, J.J. Lu, X. Yao, S. Zhang, B. Dai, Y. Shen, Y. Zhu, D. Ye, Y. Huang, Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 9, 249 (2009)

    Article  PubMed Central  PubMed  Google Scholar 

  15. H.S. Stafford, S.L. Saltzstein, S. Shimasaki, C. Sanders, T.M. Downs, G.R. Sadler, Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J. Urol. 179, 1704–1708 (2008)

    Article  PubMed Central  PubMed  Google Scholar 

  16. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009)

    Article  CAS  PubMed  Google Scholar 

  17. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, E.T. McFadden, P.P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649–655 (1982)

    Article  CAS  PubMed  Google Scholar 

  18. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, J. Ferrara, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530–2540 (1999)

    CAS  PubMed  Google Scholar 

  19. R.J. Motzer, T.E. Hutson, L. McCann, K. Deen, T.K. Choueiri, Overall survival in renal-cell carcinoma with pazopanib versus sunitinib(J). N. Engl. J. Med. 370, 1769–1770 (2014)

    Article  CAS  PubMed  Google Scholar 

  20. A. Mancuso, E.D. Di Paola, A. Leone, A. Catalano, F. Calabrò, L. Cerbone, A. Zivi, C. Messina, S. Alonso, L. Vigna, R. Caristo, C.N. Sternberg, Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. BJU Int. 109, 200–206 (2012)

    Article  CAS  PubMed  Google Scholar 

  21. B. Escudier, Sorafenib for the management of advanced renal cell carcinoma. Expert. Rev. Anticancer. Ther. 11, 825–836 (2011)

    Article  CAS  PubMed  Google Scholar 

  22. H. Akaza, T. Tsukamoto, M. Murai, K. Nakajima, S. Naito, Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn. J. Clin. Oncol. 37, 755–762 (2007)

    Article  PubMed  Google Scholar 

  23. G. Procopio, E. Verzoni, S. Bracarda, S. Ricci, C. Sacco, L. Ridolfi, C. Porta, R. Miceli, N. Zilembo, E. Bajetta, Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br. J. Cancer 104, 1256–1261 (2011)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. B.I. Rini, D.P. Cohen, D.R. Lu, I. Chen, S. Hariharan, M.E. Gore, R.A. Figlin, M.S. Baum, R.J. Motzer, Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 103, 763–773 (2011)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. D.Y. Heng, W. Xie, M.M. Regan, M.A. Warren, A.R. Golshayan, C. Sahi, B.J. Eigl, J.D. Ruether, T. Cheng, S. North, P. Venner, J.J. Knox, K.N. Chi, C. Kollmannsberger, D.F. McDermott, W.K. Oh, M.B. Atkins, R.M. Bukowski, B.I. Rini, T.K. Choueiri, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009)

    Article  CAS  PubMed  Google Scholar 

  26. D.Y. Heng, W. Xie, M.M. Regan, L.C. Harshman, G.A. Bjarnason, U.N. Vaishampayan, M. Mackenzie, L. Wood, F. Donskov, M.H. Tan, S.Y. Rha, N. Agarwal, C. Kollmannsberger, B.I. Rini, T.K. Choueiri, External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14, 141–148 (2013)

    Article  PubMed Central  PubMed  Google Scholar 

  27. S. Patil, R.A. Figlin, T.E. Hutson, M.D. Michaelson, S. Négrier, S.T. Kim, X. Huang, R.J. Motzer, Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 22, 295–300 (2011)

    Article  CAS  PubMed  Google Scholar 

  28. B.I. Rini, S.C. Campbell, B. Escudier, Renal cell carcinoma. Lancet 373, 1119–1132 (2009)

    Article  CAS  PubMed  Google Scholar 

  29. K. Nakano, K. Komatsu, T. Kubo, S. Natsui, A. Nukui, S. Kurokawa, M. Kobayashi, T. Morita, Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn. J. Clin. Oncol. 43, 1023–1029 (2013)

    Article  PubMed  Google Scholar 

  30. A. Poprach, T. Pavlik, B. Melichar, I. Puzanov, L. Dusek, Z. Bortlicek, R. Vyzula, J. Abrahamova, T. Buchler, Czech Renal Cancer Cooperative Group, skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann. Oncol. 23(3137–3143) (2012)

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

None

Author information

Authors and Affiliations

  1. Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan Dongdan, Dongcheng District, Beijing, 100730, China

    Yushi Zhang, Yongqiang Li, Yi Cai & Hanzhong Li

  2. Department of Epidemiology, Institute of Basic Medicine, Chinese Academy of Medical Sciences, Shuaifuyuan Dongdan, Dongcheng District, Beijing, 100730, China

    Ke Wang

Authors
  1. Yushi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongqiang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ke Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hanzhong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hanzhong Li.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Figure S1

mRCC patient survival in those with non-clear cell histology after sorafenib treatment. Kaplan-Meier curves of (A) progression-free survival (PFS) and (B) overall survival (OS) for 31 mRCC patients with non-clear-cell histology after sorafenib treatment. (GIF 20 kb)

High resolution image (TIFF 824 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Li, Y., Cai, Y. et al. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma. Cell Oncol. 39, 15–21 (2016). https://doi.org/10.1007/s13402-015-0245-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-015-0245-5

Keywords

Search

Navigation